Transgenic mice with high levels of superoxide dismutase activity are protected from the neurotoxic effects of 2′-NH2-MPTP on serotonergic and noradrenergic nerve terminals

Molecular Pharmacology

Volumn 50, Issue 6, 1996, Pages 1511-1519

  Andrews, Anne M ^a   Ladenheim, Bruce ^b   Epstein, Charles J ^c   Cadet, Jean Lud ^b   Murphy, Dennis L ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; BRAIN ENZYME; COPPER ZINC SUPEROXIDE DISMUTASE; NEUROTOXIN; SEROTONIN; SEROTONIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN PROTECTION; ENZYME ACTIVITY; GENETIC ANALYSIS; HIPPOCAMPUS; MOUSE; NERVE ENDING; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SEROTONIN BLOOD LEVEL; SEROTONINERGIC SYSTEM; TRANSGENIC MOUSE;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BRAIN; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MONOAMINE OXIDASE; MPTP POISONING; NERVE ENDINGS; NOREPINEPHRINE; SEROTONIN; SUPEROXIDE DISMUTASE;

EID: 0030463422     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Davis, G. C., A. C. Williams, S. P. Markey, M. H. Ebert, E. D. Caine, C. M. Reichert, and I. J. Kopin. Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res. 1:249-254 (1979).
2. Langston, J. W., P. Ballard, J. W. Tetrud, and I. Irwin. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science (Washington D. C.) 219:979-980 (1983).
3. Herkenham, M., M. D. Little, K. Bankiewicz, S. C. Yang, S. P. Markey, and J. N. Johannessen. Selective retention of MPP+ within the monoaminergic systems of the primate brain following MPTP administration: an in vivo autoradiographic study. Neuroscience 40:133-158 (1991).
4. Burns, R. S., C. C. Chiueh, S. P. Markey, M. H. Ebert, D. M. Jacobowitz, and I. J. Kopin. A primate model of Parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. USA 80:4546-4550 (1983).
5. Heikkila, R. E., A. Hess, and R. C. Duvoisin. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science (Washington D. C.) 224:1451-1453 (1984).
6. Sundstrom, E., and G. Jonsson. Pharmacological interference with the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in the mouse. Eur. J. Pharmacol 110: 293-299 (1985).
7. Booth, R. G., A. Trevor, T. P. Singer, and N. J. Castagnoli. Studies on semirigid tricyclic analogues of the nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J. Med. Chem. 32:473-477 (1989).
8. Bradbury, A. J., B. Costall, A. M. Domeney, B. Testa, P. G. Jenner, C. D. Marsden, and R. J. Naylor. The toxic actions of MPTP and its metabolite MPP+ are not mimicked by analogues of MPTP lacking an N-methyl moiety. Neurosci. Lett. 61:121-126 (1985).
9. Finnegau, K. T., I. Irwin, L. E. Delanney, G. A. Ricaurte, and J. W. Langsten. 1,2,3,6-tetrahydro-1-methyl-4-(methylpyrrol-2-yl)pyridine: studies on the mechanism of action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J. Pharmacol. Exp. Ther. 242:1144-1151 (1987).
10. Fuller, R. W., L. S. Hemrick, and D. W. Robertson. Comparison of 1-methyl-4-(p-chlorophenyl)-1,2,3,6-tetrahydropyridine, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and p-chloroamphetamine as monoamine depletors. Res. Commun. Chem. Pathol. Pharmacol. 50:57-65 (1985).
11. Harik, S. I., N. J. Riachi, M. A. Hritz, M. S. Berridge, and L. M. Sayre. Development of fluorinated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs with potent nigrostriatal toxicity for potential use in positron emission tomography studies. J. Pharmacol. Exp. Ther. 266:790-795 (1993).
12. Hemrick, L. S., D. W. Robertson, J. J. Krushinski, and R. W. Fuller. Persistent depletion of striatal dopamine and cortical norepinephrine in mice by 1-methyl-4-phenyl-1,2,3,6-tetrahydro-3-pyridinol (MPTP-3-OL), an analog of MPTP. Life Sci. 50:573-582 (1992).
13. Naiman, N., H. Rollema, E. Johnson, and N. J. Castagnoli. Studies on 4-benzyl-1-methyl-1,2,3,6-tetrahydropyridine, a nonneurotoxic analogue of the Parkineonian inducing agent 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Chem. Res. Toxicol. 3:133-138 (1990).
14. Nilsson, K., A. Hallberg, E. Pileblad, and A. Tunek. Investigation of the possible dopaminergic toxicity of 1-methyl-3-phenyl-1,2,3,6-tetrahydropyridine, an isomer to the neurotoxin MPTP. Pharmacol. Toxicol. 69:38-42 (1991).
15. Riachi, N. J., P. K. Arora, L. M. Sayre, and S. I. Harik. Potent neurotoxic fluorinated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs as potential probes in models of Parkinson disease. J. Neurochem. 50:1319-1321 (1988).
16. Rollema, H., R. G. Booth, and N. J. Castagnoli. In vivo dopaminergic neurotoxicity of the 2-beta-methylcarbolinium ion, a potential endogenous MPP+ analog. Eur. J. Pharmacol. 153:131-134 (1988).
17. Youngster, S. K., P. K. Sonealla, B. A. Sieber, and R. E. Heikkila. Structure-activity study of the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity. I. Evaluation of the biological activity of MPTP analogs. J. Pharmacol. Exp. Ther. 249:820-828 (1989).
18. Johannessen, J. N., J. M. Savitt, C. J. Markey, J. P. Bacon, A. Weisz, D. S. Hanselman, and S. P. Markey. The development of amine substituted analogues of MPTP as unique tools for the study of MPTP toxicity and Parkinson's disease. Life Sci. 40:697-704 (1987).
19. Heikkila, R. E., M. V. Kindt, P. K. Sonsalla, A. Giovanni, S. K. Youngster, K. A. McKeown, and T. P. Singer. Importance of monoamine oxidase A in the bioactivation of neurotoxic analogs of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. USA 85:6172-6176 (1988).
20. 2-MPTP): a comparative study with 2′-CHS-MPTP and MPTP. J. Neurochem. 60: 1167-1170 (1993).
21. 2-MPTP in Swiss Webster mice: evidence for long term (six month) depletions in cortical and hippocampal 5-HT and NE, differential protection by selective uptake inhibitors or clorgyline, and functional changes in central 5-HT neurotransmission. J. Pharmacol. Exp. Ther. 267:1432-1439 (1993).
22. 2-MPTP-induced depletions in serotonin and norepinephrine. Eur. J. Pharmacol. 250:215-221 (1993).
23. Heikkila, R. E., L. Manzino, F. S. Cabbat, and R. C. Duvoisin. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature (Lond.) 311: 467-469 (1984).
24. Markey, S. P., J. N. Johannessen, C. C. Chiueh, R. S. Burns, and M. A. Herkenham. Intraneuronal generation of a pyridinium metabolite may cause drug-induced Parkinsonism. Nature (Lond.) 311:464-467 (1984).
25. Javitch, J. A., R. J. D'Amato, S. M. Strittmatter, and S. H. Snyder. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc. Natl. Acad. Sci. USA 82:2173-2177 (1985).
26. Chiueh, C. C., G. Krishna, P. Tulsi, T. Obata, K. Lang, S. J. Huang, and D. L. Murphy. Intracranial microdialysis of salicylic acid to detect hydroxyl radical generation through dopamine autooxidation in the caudate nucleus: effects of MPP+. Free Radical Biol. Med. 13:581-583 (1992).
27. Cleeter, M. W., J. M. Cooper, and A. H. Schapira. Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: evidence for free radical involvement. J. Neurochem. 58:786-789 (1992).
28. Ali, S. F., S. N. David, G. D. Newport, J. L. Cadet, and W. Slikker, Jr. MPTP-induced oxidative stress and neurotoxicity are age-dependent: evidence from measures of reactive oxygen species and striatal dopamine levels. Synapse (N. Y.) 18:27-34 (1994).
29. Przedborski, S., V. Kostic, L. V. Jackson, A. B. Naini, S. Simonetti, S. Fahn, E. Carlson, C. J. Epstein, and J. L. Cadet. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J. Neurosci. 12:1658-1667 (1992).
30. Epstein, C. J., K. B. Avraham, M. Lovett, S. Smith, S. O. Elroy, G. Rotman, C. Bry, and Y. Groner. Transgenic mice with increased Cu/Zn-superoxide dismutase activity: animal model of dosage effects in Down syndrome. Proc. Natl. Acad. Sci. USA 84:8044-8048 (1987).
31. Halliwell, B. Reactive oxygen species and the central nervous system. J. Neurochem. 59:1609-1623 (1992).
32. Cadet, J. L., P. Sheng, S. Ali, R. Rothman, E. Carlson, and C. Epstein. Attenuation of methamphetamine-induced neurotoxicity in copper/zinc Superoxide dismutase transgenic mice. J. Neurochem. 62:380-383 (1994).
33. Cadet, J. L., B. Ladenheim, H. Hirata, R. B. Rothman, S. A. Ali, E. Carlson, C. Epstein, and T. H. Moran. Superoxide radicals mediate the biochemical effects of methylenedioxymethamphetamine (MDMA): evidence from using CuZn-superoxide dismutase transgenic mice. Synapse (N. Y.) 21:169-176 (1995).
34. Chan, P. H., C. J. Epstein, H. Kinouchi, H. Kamii, S. Imaizumi, G. Yang, S. F. Chen, J. Gafni, and E. Carlson. SOD-1 transgenic mice as a model for studies of neuroprotection in stroke and brain trauma. Ann. N. Y. Acad. Sci. (Washington D. C.) 738:93-103 (1994).
35. Lowry, O. H., N. J. Rosebrough, A. L. Farr, and R. J. Randall. Protein measurement with the folin phenol reagent. J. Biol. Chem. 193:265-275 (1951).
36. Silverthorn, M. L., C. M. Dersch, M. H. Baumann, J. L. Cadet, J. S. Partilla, K. C. Rice, F. I. Carroll, K. M. Becketts, A. Brockington, and R. B. Rothman. Studies of the biogenic amine transporters. V. Demonstration of two binding sites for the cocaine analog [125 I]RTI-55 associated with the 5-HT transporter in rat brain membranes. J. Pharmacol. Exp. Ther. 273: 213-222 (1995).
37. Sonsalla, P. K., S. K. Youngster, M. V. Kindt, and R. E. Heikkila. Characteristics of 1-methyl-4-(2′-methylphenyl)-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the mouse. J. Pharmacol. Exp. Ther. 242:850-857 (1987).
38. Battaglia, G. Criteria for assessing drug-induced biochemical alterations and degeneration of serotonergic neurons, in Serotonin: From Cell Biology to Pharmacology and Therapeutics (R. Paoletti, P. M. Vanhoutte, N. Brunello, and F. M. Maggi, eds.). Kluwer Academic, Dordrecht, The Netherlands, 651-660 (1990).
39. Hirata, H., B. Ladenheim, R. B. Rothman, C. Epstein, and J. L. Cadet. Methamphetamine-induced serotonin neurotoxicity is mediated by superoxide radicals. Brain Res. 677:345-347 (1995).
40. Bates, T. E., S. J. R. Heales, S. E. C. Davies, P. Boakye, and J. B. Clark. Effects of 1-methyl-4-phenylpyridinium on isolated rat brain mitochondria: evidence for a primary involvement of energy depletion. J. Neurochem. 63:640-648 (1994).
41. O'Dell, S. J., F. B. Weihmuller, and J. F. Marshall. Methamphetamine-induced dopamine overflow and injury to striatal dopamine terminals: attenuation by dopamine D1 or D2 antagonists. J. Neurochem. 60:1792-1799 (1993).
42. Baldwin, H. A., M. I. Colado, T. K. Murray, R. J. De Souza, and A. R. Green. Striatal dopamine release in vivo following neurotoxic doses of methamphetamine and effect of the neuroprotective drugs, chlormethiazole and dizocilpine. Br. J. Pharmacol. 108:590-596 (1993).
43. Obata, T., Y. Yamanaka, and C. C. Chiueh. In vivo release of dopamine by perfusion of 1-methyl-4-phenylpyridinium ion in the striatum with a microdialysis technique. Jpn. J. Pharmacol. 60:311-313 (1992).
44. Schmidt, C. J., C. K. Sullivan, and G. M. Fadayel. Blockade of striatal 5-hydroxytryptamine2 receptors reduces the increase in extracellular concentrations of dopamine produced by the amphetamine analogue 3,4-methylenedioxymethamphetamine. J. Neurochem. 62:1382-1389 (1994).
45. Wrona, M. Z., D. Lemordant, L. Lin, C. L. Blank, and G. Dryhurst. Oxidation of 5-hydroxytryptamine and 5,7-dihydroxytryptamine. A new oxidation pathway and formation of a novel neurotoxin. J. Med. Chem. 29:499-505 (1986).
46. Graham, D. G. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol. Pharmacol. 14:633-643 (1978).
47. Graham, D. G., S. M. Tiffany, W. R. Bell, Jr., and W. F. Gutknecht. Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol. Pharmacol. 14:644-653 (1978).
48. Arora, P. K., N. J. Riachi, G. C. Fiedler, M. P. Singh, F. Abdallah, S. I. Harik, and L. M. Sayre. Structure-neurotoxicity trends of analogues of 1-methyl-4-phenylpyridinium (MPP+), the cytotoxic metabolite of the dopaminergic neurotoxin MPTP. Life Sci. 46:379-390 (1990).
49. Saporito, M. S., R. E. Heikkila, S. K. Youngster, W. J. Nicklas, and H. M. Geller. Dopaminergic neurotoxicity of 1-methyl-4-phenylpyridinium analogs in cultured neurons: relationship to the dopamine uptake system and inhibition of mitochondrial respiration. J. Pharmacol. Exp. Ther. 260: 1400-1409 (1992).
50. Nicklas, W. J., I. Vyas, and R. E. Heikkila. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci. 36:2503-2508 (1985).
51. Hasegawa, E., K. Takeshige, T. Oishi, Y. Murai, and S. Minakami. 1-Methyl-4-phenylpyridinium (MPP+) induces NADH-dependent Superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles. Biochem. Biophys. Res. Commun. 170:1049-1055 (1990).
52. Axt, K. J., D. L. Commins, G. Vosmer, and L. S. Seiden. alpha-Methyl-p-tyrosine pretreatment partially prevents methamphetamine-induced endogenous neurotoxin formation. Brain Res. 615:269-276 (1990).
53. Commins, D. L., K. J. Axt, G. Vosmer, and L. S. Seiden. Endogenously produced 5,6-dihydroxytryptamine may mediate the neurotoxic effects of para-chloroamphetamine. Brain Res. 419:253-261 (1987).
54. Schickler, M., H. Knobler, K. B. Avraham, O. Elroy-Stein, and Y. Groner. Diminished serotonin uptake in platelets of transgenic mice with increased Cu/Zn-superoxide dismutase activity. Embo. J. 8:1385-1392 (1989).
55. Schwartz, P. J., U. V. Berger, and J. T. Coyle. Mice transgenic for copper/ zinc Superoxide dismutase exhibit increased markers of biogenic amine function. J. Neurochem. 65:660-669 (1995).